Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis | Zendy

Daniel Pink | Zendy; Stephan Richter | Zendy; Sebastian Gerdes | Zendy; Dimosthenis Andreou | Zendy; PerUlf Tunn | Zendy; Christoph Busemann | Zendy; Gerhard Ehninger | Zendy; Peter Reichardt | Zendy; Markus K. Schuler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis

Author(s) -

Daniel Pink,

Stephan Richter,

Sebastian Gerdes,

Dimosthenis Andreou,

PerUlf Tunn,

Christoph Busemann,

Gerhard Ehninger,

Peter Reichardt,

Markus K. Schuler

Publication year - 2014

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000362602

Subject(s) - docetaxel , gemcitabine , medicine , retrospective cohort study , oncology , epithelioid sarcoma , sarcoma , chemotherapy , radiology , pathology

Epithelioid sarcoma (ES) presents unique clinical features in comparison to other sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, especially in uterine and nonuterine leiomyosarcoma. Yet, there is no available data on the efficacy of Gem/Doce in ES.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research